← Back to Search

FAZA-PET/MRI Imaging for Sarcoma

N/A

Recruiting

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with high-risk extremity STS (g2-3, > 10 cm largest dimension, and leiomyosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumour, or undifferentiated pleomorphic sarcoma), or high-risk RPS (g2-3, and leiomyosarcoma or dedifferentiated liposarcoma)

Age ≥ 18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial is investigating the use of FAZA-PET in combination with MRI to measure hypoxia in sarcoma tissues.

Who is the study for?

Adults with high-risk sarcoma (specific types like leiomyosarcoma or dedifferentiated liposarcoma) who are planning to undergo radiotherapy, chemotherapy, or surgery. Participants must be able to lie down for at least an hour and not be pregnant or breastfeeding. Those with previous cancer treatments or other active cancers cannot join.Check my eligibility

What is being tested?

The trial is testing FAZA-PET combined with MRI to measure oxygen levels in sarcoma tissues before treatment starts. One group will have the scan before radiation/chemotherapy, while another may have it before surgery. Some patients will also receive pimonidazole prior to surgery.See study design

What are the potential side effects?

Potential side effects from FAZA are monitored via a follow-up call two days after the PET/MRI scan. Pimonidazole's side effects will be assessed around the time of surgery.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a high-risk soft tissue sarcoma in my limbs or a high-risk retroperitoneal sarcoma.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Grade of FAZA uptake in the primary tumor

Trial Design

2Treatment groups

Experimental Treatment

Group I: Arm BExperimental Treatment1 Intervention

Participants will receive pimonidazole prior to surgery. Participants in Arm B also have the option to complete a FAZA PET/MRI scan prior to surgery.

Group II: Arm AExperimental Treatment1 Intervention

Participants will complete FAZA PET/MRI scan and radiation therapy before surgery.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pimonidazole

Not yet FDA approved

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,476 Previous Clinical Trials

485,140 Total Patients Enrolled

14 Trials studying Sarcoma

605 Patients Enrolled for Sarcoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment welcoming new participants?

"Affirmative. Clinicialtrials.gov states that this medical trial is actively recruiting study participants, having initially been posted on March 27th 2018 and most recently edited on October 6th 2022."

Answered by AI

To what extent are individuals participating in this research endeavor?

"Yes, according to clinicaltrials.gov the trial is still actively recruiting patients. The study was posted on March 27th 2018 and its details were last updated October 6th 2022. Currently, it seeks 30 participants from a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

FAZA PET/MRI Sarcoma

2018. "FAZA PET/MRI Sarcoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03418818.

All > Sarcoma